Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Harvard Business School
Express Scripts
Moodys
McKinsey

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR INFANT'S ADVIL


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Infant's Advil

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01732874 ↗ DHA Supplementation for Lactating Mothers Completed Children's Hospital Medical Center, Cincinnati Phase 1/Phase 2 2013-05-01 The purpose of this research study is to find out whether preterm infants are receiving enough of the essential and long chain fatty acids important for brain development and immune function. Our current intravenous (IV) fats do not contain the long chain fatty acids and different milk sources have different compositions. We would like to evaluate lactating mothers dietary intake and breastmilk level of fatty acid status by doing an analysis of their blood and breastmilk samples after they have been supplemented with a currently used fatty acid supplement (DHA- Martek Biosciences, now known as Dutch State Mines (DSM) Nutritional Lipid) The DHA supplement is available over the counter. The information learned from this research study may benefit other mothers and babies in the future. The information could help make sure premature babies are receiving the right nutrients they need for appropriate growth and development.
New Dosage NCT03608696 ↗ Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Completed Chiesi Farmaceutici S.p.A. Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
New Dosage NCT03608696 ↗ Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure Completed Thomas Jefferson University Phase 1/Phase 2 2018-08-29 Neonatal withdrawal syndrome is a series of signs and symptoms in infants exposed to opioids in utero. Buprenorphine has demonstrated a 40% reduction in length of pharmacologic treatment compared to oral morphine. These results were with an empirically derived dose. This study will use pharmacokinetic modeling-informed dosing to clarify the dose/response relationship and use a rational approach to define an optimal dose regimen. The clinical trial will be open label, single arm design with a goal of initial testing of a new dosing regimen.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Infant's Advil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000494 ↗ Management of Patent Ductus in Premature Infants Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1978-09-01 To evaluate the effects (up to one year of age) of indomethacin on the clinical course of patent ductus arteriosus (PDA) in premature infants (24 hours old or less) and to assess the relative merits of indomethacin and surgery in infants with persistent respiratory distress who were not treated early with indomethacin. Two concurrent trials were performed.
NCT00000563 ↗ Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1976-06-01 To determine the effect of corticosteroids, administered 24 to 48 hours before parturition, on the incidence of neonatal respiratory distress syndrome (RDS) and to determine whether the therapy has any adverse short- or long-term (up to 36 months) effects on the infant. Secondarily, to determine whether the therapy has any adverse short-term effects on the mother and to determine whether morbidity rates for neonatal respiratory distress syndrome as well as total and cause-specific infant mortality rates differ between mothers who received antenatal steroids and those who received conventional medical care.
NCT00000578 ↗ NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1994-04-01 To conduct a collaborative program of research on asthma and pregnancy consisting of two studies: the Asthma in Pregnancy Study (APS) was an observational study to evaluate relationships between asthma severity and treatment programs and perinatal outcome, and the Asthma Therapy in Pregnancy Trial (ATPT) was a randomized clinical trial of inhaled beclomethasone versus theophylline in the treatment of moderate asthma during pregnancy. Both studies were conducted in the Maternal-Fetal Medicine Unit (MFMU) Network, an ongoing group of participating obstetric centers supported by the National Institute of Child Health and Human Development. Studies were co-funded by the NHLBI.
NCT00000578 ↗ NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1994-04-01 To conduct a collaborative program of research on asthma and pregnancy consisting of two studies: the Asthma in Pregnancy Study (APS) was an observational study to evaluate relationships between asthma severity and treatment programs and perinatal outcome, and the Asthma Therapy in Pregnancy Trial (ATPT) was a randomized clinical trial of inhaled beclomethasone versus theophylline in the treatment of moderate asthma during pregnancy. Both studies were conducted in the Maternal-Fetal Medicine Unit (MFMU) Network, an ongoing group of participating obstetric centers supported by the National Institute of Child Health and Human Development. Studies were co-funded by the NHLBI.
NCT00000580 ↗ Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1975-11-01 To evaluate whether hepatitis B immune globulin with a high level of antibody against the hepatitis B antigen would be capable of interrupting maternal-fetal transmission of hepatitis B virus, the single most important route of hepatitis spread in the entire Third World.
NCT00000590 ↗ Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
NCT00000590 ↗ Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Infant's Advil

Condition Name

Condition Name for Infant's Advil
Intervention Trials
HIV Infections 67
Pregnancy 55
Pain 24
Malaria 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Infant's Advil
Intervention Trials
HIV Infections 72
Premature Birth 72
Malaria 35
Infections 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Infant's Advil

Trials by Country

Trials by Country for Infant's Advil
Location Trials
Thailand 109
Canada 82
Italy 51
South Africa 46
Argentina 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Infant's Advil
Location Trials
California 96
Texas 78
New York 68
North Carolina 67
Pennsylvania 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Infant's Advil

Clinical Trial Phase

Clinical Trial Phase for Infant's Advil
Clinical Trial Phase Trials
Phase 4 152
Phase 3 165
Phase 2/Phase 3 32
[disabled in preview] 353
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Infant's Advil
Clinical Trial Phase Trials
Completed 419
Recruiting 103
Terminated 74
[disabled in preview] 137
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Infant's Advil

Sponsor Name

Sponsor Name for Infant's Advil
Sponsor Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 70
National Institute of Allergy and Infectious Diseases (NIAID) 57
National Heart, Lung, and Blood Institute (NHLBI) 17
[disabled in preview] 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Infant's Advil
Sponsor Trials
Other 1321
NIH 214
Industry 152
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
Express Scripts
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.